news
Discovery enables further investigation into new ligases
Researchers have developed a new PROTAC that activates the protein degradation system and binds to a previously inaccessible ligase.
List view / Grid view
Small Molecules
news
New technology to effectively regulate gene expression
A new strategy enables researchers to be more precise in the control of gene expression of a therapeutic protein.
article
The effectiveness of nanoparticles in chemotherapy
Understanding more about the effect of liposome nanoparticles on the immune system will improve drug delivery systems.
news
Potential of small molecule therapeutics for Barth syndrome
Novel findings about the tafazzin gene offers a potential new target and drug candidate for Barth syndrome.
news
Rare genetic variant blocks common Alzheimer’s disease risk factor
New understanding of “Christchurch mutation” in the APOE gene may lead to novel Alzheimer's disease treatments.
news
Dynamic molecular aggregates within cells
Researchers from the University of Freiburg and the University of Cambridge have observed live cell formation of membraneless molecular aggregates, uncovering the interplay between biological mechanisms and physical force.
webinar
Functional assays for the development of agonistic antibodies
20 July 2023 | By Eurofins DiscoverX
Watch this webinar to discover qualified bioassays assessing therapeutic antibody mechanisms, case studies about agonistic effects in antibodies initially deemed antagonistic, and explore Fc receptor impacts on antibody response in co-culture assays.
article
Condensate biology: advancing drug discovery for complex diseases
In this interview with Drug Target Review’s Izzy Wood and Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, discuss the innovative potential of condensate biology in revolutionising drug discovery. By targeting disease-driving condensates, Dewpoint’s research pushes boundaries by offering new hope for tackling diseases like ALS and colorectal cancer.
whitepaper
Application note: Novel screening tools for TMEM175 drug discovery
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.
article
RNA processing in health and disease: challenges and opportunities of the field
In this interview, Sam Hasson, Senior Director at Rgenta Therapeutics, shares his journey in drug discovery, from graduate school to industry, and his current work developing small molecule therapeutics to target RNA processing. He discusses the challenges and opportunities in the field of RNA-centric drug discovery and highlights the potential…
news
USC researchers zoom into human genome with mammal DNA
USC researcher Dr Steven Gazal and his team have identified human genome base pairs that have remained constant over millions of years of mammalian evolution. These base pairs are linked to human disease. Using DNA from 240 mammal species, they identified genetic variations affecting an individual's survival and reproduction.
news
Researchers discover small molecules that bind to SARS-CoV-2 spike proteins
The resulting compounds, which can bind to spike proteins from the original coronavirus, could serve as a starting point for developing broad-spectrum treatments for COVID-19.
webinar
Validated bioassays for metabolic & gastrointestinal diseases: Accelerating development of GLP-1 & -2 therapeutics
20 December 2022 | By Eurofins DiscoverX Corp.
In this webinar, we present an approach for building MOA-based, simple, ready-to-use GLP-1 and GLP-2 bioassays and discuss assay validation results from Eurofins BPT.
news
New findings show a monoclonal antibody could target heroin addiction
The study highlights that a monoclonal antibody that targets heroin is effective in blocking the psychoactive and lethal effects of drug abuse in mice.
news
Discovery of two drugs could lead to earlier pancreatic cancer treatment
In pre-clinical studies, the University of Florida has identified two drugs that reverse ADM, a process that precedes pancreatic cancer.